Literature DB >> 27405025

68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer.

Hojjat Ahmadzadehfar1, Carl Diedrich Schlenkhoff, Sebastian Rogenhofer, Anna Yordanova, Markus Essler.   

Abstract

A 64-year-old man with prostate cancer and an increasing prostate-specific antigen (PSA) level under therapy with abiraterone acetate underwent a therapy with Ra. Before the first therapy and 4 weeks after the last cycle, the patient underwent Ga-PSMA PET, which showed a clear response of bone metastases.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27405025     DOI： 10.1097/RLU.0000000000001286

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  6 in total

1.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

Review 2.  18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Br J Radiol       Date:  2018-04-16       Impact factor: 3.039

Review 3.  Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold.

Authors:  Carlo Aprile; Marco G Persico; Lorenzo Lodola; Federica E Buroni
Journal:  World J Radiol       Date:  2016-10-28

4.  Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution.

Authors:  Gonçalo Ferreira; Amir Iravani; Michael S Hofman; Rodney J Hicks
Journal:  Cancer Imaging       Date:  2019-05-15       Impact factor: 3.909

5.  Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride.

Authors:  Ana María García Vicente; Mariano Amo-Salas; Javier Cassinello Espinosa; Roberto Gómez Díaz; Ángel Soriano Castrejón
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

6.  Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.

Authors:  Hojjat Ahmadzadehfar; Stefanie Zimbelmann; Anna Yordanova; Rolf Fimmers; Stefan Kürpig; Elisabeth Eppard; Florian C Gaertner; Xiao Wei; Stefan Hauser; Markus Essler
Journal:  Oncotarget       Date:  2017-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.